Đang chuẩn bị liên kết để tải về tài liệu:
Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS

Under the Pharmaceutical Zero-for-Zero Initiative, which entered into force in 1995, the United States and its major trading partners eliminated tariffs on many pharmaceuticals, their derivatives, and certain chemical intermediates used to make pharmaceuticals. The U.S. list of pharmaceutical products and chemical intermediates that are eligible for duty- free treatment under the agreement is presented in the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States. This appendix is periodically updated to provide duty relief for additional products of this kind, including newly developed pharmaceuticals. This report provides advice on the fourth update to the agreement, in which approximately. | United States International Trade Commission Pharmaceutical Products and Chemical Intermediates Fourth Review Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS Investigation No. 332-520 USITC Publication 4181 September 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Irving A. Williamson Dean A. Pinkert Robert B. Koopman Acting Director of Operations Karen Laney Director Office of Industries Address all communications to Secretary to the Commission United States International Trade Commission Washington DC 20436 U.S. International Trade Commission Washington DC 20436 www.usitc.gov Pharmaceutical Products and Chemical Intermediates Fourth Review Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS Investigation No. 332-520 Publication 4181 September .